Physician profile
Harminder S Sethi
NPI 1275563033
$15,667.29
in general payments reported to CMS, 2019-2025
64 companies · $4,458 in 2025
The $4,458 reported for 2025 was more than what 80% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $496 · 2020: $213 · 2021: $11.92 · 2022: $1,834 · 2023: $3,870 · 2024: $4,785 · 2025: $4,458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Long Term Medical Supply Or Device Loan: $865 · Consulting Fee: $300 · Education: $97.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,851.03 |
| Long Term Medical Supply Or Device Loan | $864.56 |
| Consulting Fee | $300.00 |
| Education | $97.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,023.01 | 2019-2025 | |
| Janssen Biotech, INC. | $1,753.65 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Pfizer INC. | $1,000.20 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $788.58 | 2022-2025 | Voydeya, Ultomiris |
| Daiichi Sankyo INC. | $767.08 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Abbvie INC. | $678.59 | 2022-2025 | Venclexta, Lupron Depot |
| Astrazeneca Pharmaceuticals LP | $656.43 | 2019-2025 | Calquence, Lynparza, Enhertu |
| Merck Sharp & Dohme LLC | $588.84 | 2019-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $477.33 | 2022-2025 | Opdivo, Eliquis, Augtyro |
| Regeneron Healthcare Solutions, INC. | $448.23 | 2022-2025 | Libtayo |
| Incyte Corporation | $441.75 | 2020-2025 | Jakafi, Monjuvi, Niktimvo |
| Glaxosmithkline, LLC. | $433.50 | 2022-2025 | Zejula, Jemperli, Ojjaara |
| Takeda Pharmaceuticals U.S.A., INC. | $396.46 | 2019-2025 | Fruzaqla, Ninlaro, Iclusig |
| Amgen INC. | $317.40 | 2022-2025 | Evenity, Lumakras, Prolia |
| Pharmacyclics LLC, An Abbvie Company | $264.45 | 2019-2023 | Imbruvica, Epkinly |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure Gmbh | $250.00 | 2022 | |
| Exelixis INC. | $242.02 | 2023-2025 | Cabometyx |
| Adaptive Biotechnologies Corporation | $238.90 | 2022-2025 | Clonoseq |
| Lilly USA, LLC | $219.74 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Shield Therapeutics INC | $210.80 | 2023-2025 | Accrufer |
| Celgene Corporation | $188.19 | 2019-2025 | Reblozyl, Opdualag |
| Eisai INC. | $187.15 | 2019-2025 | |
| Rigel Pharmaceuticals, INC. | $160.66 | 2022-2025 | Rezlidhia, Gavreto, Tavalisse |
| Genzyme Corporation | $156.46 | 2022-2025 | |
| Array Biopharma INC | $135.19 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Sumitomo Pharma America, INC. | $130.52 | 2024-2025 | Orgovyx |
| Pharmacosmos Therapeutics INC. | $126.85 | 2022-2025 | Monoferric |
| Pharmaessentia USA Corporation | $125.57 | 2023-2025 | Besremi |
| Kite Pharma, INC. | $122.85 | 2023 | Yescarta |
| Genentech USA, INC. | $119.83 | 2022-2025 | Venclexta, Tecentriq, Polivy |
| Mirati Therapeutics, INC. | $116.91 | 2023 | Krazati |
| Intera Oncology, INC | $114.21 | 2024 | Intera |
| Seagen INC. | $112.68 | 2022-2023 | Tukysa, Adcetris |
| Stemline Therapeutics INC. | $107.01 | 2023-2025 | Orserdu |
| Astellas Pharma US INC | $105.49 | 2023-2025 | Padcev, Vyloy |
| Tersera Therapeutics LLC | $97.29 | 2022-2025 | Xermelo |
| Clovis Oncology, INC. | $95.00 | 2019 | |
| Acrotech Biopharma INC. | $92.74 | 2023-2025 | Beleodaq |
| Sobi, INC | $91.60 | 2022-2025 | |
| Taiho Oncology, INC. | $84.83 | 2023 | |
| Alnylam Pharmaceuticals INC. | $75.59 | 2023-2024 | Givlaari |
| Blueprint Medicines Corporation | $73.45 | 2022-2025 | Ayvakit |
| Beigene USA, INC. | $68.02 | 2024-2025 | Tevimbra, Brukinsa |
| Janssen Scientific Affairs, LLC | $66.99 | 2019 | |
| Puma Biotechnology, INC. | $58.78 | 2020-2025 | |
| Recordati_rare_diseases_inc. | $56.36 | 2023-2024 | Sylvant |
| Caris Mpi, INC. | $52.37 | 2025 | Mi Cancer Seek |
| Beone Medicines USA, INC. | $50.40 | 2025 | Tevimbra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.24 | 2023-2024 | |
| G1 Therapeutics, INC. | $47.72 | 2022-2023 | Cosela |
| Spectrum Pharmaceuticals INC. | $44.20 | 2023 | Rolvedon |
| Azurity Pharmaceuticals, INC. | $39.94 | 2024-2025 | Vivimusta, Danziten |
| Karyopharm Therapeutics INC. | $36.88 | 2023 | Xpovio |
| Bayer Healthcare Pharmaceuticals INC. | $35.92 | 2019 | |
| Emd Serono, INC. | $33.34 | 2024 | |
| Stryker Corporation | $32.65 | 2025 | |
| Syndax Pharmaceuticals, INC. | $29.75 | 2025 | |
| Aveo Pharmaceuticals, INC. | $25.60 | 2024 | |
| Janssen Pharmaceuticals, INC | $24.92 | 2020 | |
| Heron Therapeutics, INC. | $23.96 | 2022 | |
| Invivyd INC | $23.64 | 2024 | Pemgarda |
| Adc Therapeutics America, INC. | $21.11 | 2025 | |
| Cardiovascular Systems INC. | $17.55 | 2023 | Diamondback Coronary |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harminder Sethi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.